National Bank Financial has put its price target on QLT Inc. "under review" on Thursday, pending the release of third-quarter results in a week's time. Analyst Prakash Gowd had the target at $5.60 (U.S.). The rating is "underperform." Marketing partner Novartis AG says the Visudyne anti-blindness drug developed by QLT had global third-quarter sales of $48.7-million, down 35 per cent year-over-year. Mr. Gowd calls that "lower than our bearish expectations," reflecting competitive pressures and restrictions on insurance reimbursement on the drug. The stock has fallen 1.4 per cent to $4.81 on the Nasdaq.